最近PD-(L)1/VEGF双抗热闹极了。1月12日,国内两款PD-(L)1/VEGF双抗双双放出好消息:荣昌生物的PD-1/VEGF双抗RC148的大中华区外全球权益授予艾伯维,交易总金额达到56亿美元;另一边,Summit宣布去年第四季度已经向FDA递交引进自康方生物的依沃西单抗上市申请。加上1月9日,宜明昂科PD-(L)1/VEGF双抗海外合作宣告终结,几则消息瞬间点燃了PD-(L)1/...
Source Link最近PD-(L)1/VEGF双抗热闹极了。1月12日,国内两款PD-(L)1/VEGF双抗双双放出好消息:荣昌生物的PD-1/VEGF双抗RC148的大中华区外全球权益授予艾伯维,交易总金额达到56亿美元;另一边,Summit宣布去年第四季度已经向FDA递交引进自康方生物的依沃西单抗上市申请。加上1月9日,宜明昂科PD-(L)1/VEGF双抗海外合作宣告终结,几则消息瞬间点燃了PD-(L)1/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.